ClinicalTrials.gg

Program

Oxymetazoline

Also written as “OXY combination: mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY)”, “Oxymetazoline Hydrochloride” and “Oxymetazoline HCL Cream 1.0%”.

Its studies are mostly in Rosacea · Erythema · Fecal Incontinence · Rhinitis, Allergic · Nasal Obstruction, led by 10 companies.

Furthest: phase 4, since Mar 21, 201416 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie60 open or runningphase 3since Mar 21, 2014Apr 13, 2012none ahead
RDD Pharma20 open or runningphase 2since Nov 17, 2014Nov 17, 2014none ahead
Aclaris Therapeutics10 open or runningphase 4since Dec 18, 2017Dec 18, 2017none ahead
Bayer10 open or runningphase 2since May 6, 2026May 6, 2026none ahead
eye-therapies-llc10 open or runningphase 2since Jan 10, 2011Jan 10, 2011none ahead
Johnson & Johnson10 open or runningphase 1since May 30, 2014May 30, 2014none ahead
Padagis10 open or runningphase 3since Nov 7, 2017Nov 7, 2017none ahead
Santen Pharmaceutical11 open or runningphase 3since Jul 3, 2024Jul 3, 2024none ahead
Sun Pharmaceutical Industries10 open or runningphase 1since Nov 23, 2021Nov 23, 2021none ahead
Teva Pharmaceutical Industries10 open or runningphase 3since Apr 10, 2019Apr 10, 2019none ahead

Also a collaborator on its studies: quintiles-inc, ground-zero-pharmaceuticals, rho-inc and ORA.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 1 study since Jan 10, 2011.

  1. Apr 13, 2012AbbVie's first study: phase 1 study in RosaceaNew to AbbVieAbbVie · NCT01579084 · 64 enrolled · United States
  2. Nov 26, 2012Phase 2 study in RosaceaAbbVie · NCT01735201 · 357 enrolled · United States
  3. Mar 21, 2014Phase 3 study in ErythemaAbbVie · NCT02095158 · 440 enrolled · United States
  4. May 5, 20142 phase 3 studies in ErythemaAbbVie · NCT02132117, NCT02131636
  5. May 30, 2014Johnson & Johnson's first study: phase 1 study in Rhinitis, AllergicNew to Johnson & JohnsonJohnson & Johnson · NCT02154334 · 47 enrolled · Germany
  6. Jul 21, 2014Phase 2 study in PresbyopiaAbbVie · NCT02197806 · 65 enrolled · United States
  7. Nov 17, 2014RDD Pharma's first study: phase 2 study in Fecal IncontinenceNew to RDD PharmaRDD Pharma · NCT02299557 · 19 enrolled · Hungary
  8. Nov 7, 2017Padagis's first study: phase 3 study in RosaceaNew to PadagisPadagis · NCT03352323 · 50 enrolled · United States
  9. Dec 18, 2017Aclaris Therapeutics's first study: phase 4 study in RosaceaNew to Aclaris TherapeuticsAclaris Therapeutics · NCT03380390 · 46 enrolled · United States
  10. May 7, 2018Phase 1 study in Fecal IncontinenceRDD Pharma · NCT03529487 · 40 enrolled · United States
  11. Apr 10, 2019Teva Pharmaceutical Industries's first study: phase 3 study in RosaceaNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT03954444 · 1,105 enrolled · United States
  12. Nov 23, 2021Sun Pharmaceutical Industries's first study: phase 1 study in BioequivalenceNew to Sun Pharmaceutical IndustriesSun Pharmaceutical Industries · NCT05148689 · 82 enrolled · United States
  13. Jul 3, 2024Santen Pharmaceutical's first study: phase 3 study in Acquired BlepharophimosisNew to Santen PharmaceuticalSanten Pharmaceutical · NCT06514612 · 234 planned · Czechia, France, Germany and more
  14. May 6, 2026Bayer's first study: phase 2 study in Nasal ObstructionNew to BayerBayer · NCT07582328 · 120 enrolled · Canada

TargetBeta

“Adrenergic receptor alpha agonist”ChEMBL 37, by rule

Other programs on the same 6 targets

ProgramCompanyFurthest phaseStudies
Phentolamineruleopus-genetics-incphase 418
Epinephrinerulenasus-pharmaphase 417

Studies

All 16 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07582328Nasal Obstruction · Canada2CompletedBayerMay 28, 2026120
NCT06514612Acquired Blepharophimosis · Czechia, France, Germany and more3RecruitingSanten PharmaceuticalAug 1, 2026234
NCT05148689Bioequivalence · United States1CompletedSun Pharmaceutical IndustriesMar 21, 201982
NCT03954444Rosacea · United States3CompletedTeva Pharmaceutical IndustriesJan 7, 20201,105
NCT03529487Fecal Incontinence · United States1UNKNOWNRDD PharmaDec 1, 202340
NCT03380390Rosacea · United States4CompletedAclaris TherapeuticsJun 15, 201846
NCT03352323Rosacea · United States3CompletedPadagisDec 6, 201750
NCT02299557Fecal Incontinence · Hungary2CompletedRDD PharmaJun 201519
NCT02197806Presbyopia · United States2CompletedAbbVieOct 201465
NCT02154334Rhinitis, Allergic · Germany1CompletedJohnson & JohnsonOct 201447
NCT02132117Erythema · United States3CompletedAbbVieApr 2015445
NCT02131636Erythema · United States3CompletedAbbVieNov 2014440
NCT02095158Erythema · United States3CompletedAbbVieAug 2015440
NCT01735201Rosacea · United States2CompletedAbbVieMay 2013357
NCT01579084Rosacea · United States1CompletedAbbVieJun 201264
NCT01275105Conjunctivitis, Allergic · United States2Completedeye-therapies-llcMar 201168

How it is read

Names in the registry

  • “Oxymetazoline”, 3 entries
  • “OXY combination: mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY)”, 2 entries
  • “Oxymetazoline Hydrochloride”, 2 entries
  • “Oxymetazoline HCL Cream 1.0%”, 2 entries
  • “AGN-199201”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.